Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP2017 autoinjector versus pre-filled syringe pharmacokinetics study in healthy men
NL-OMON42002Active, not recruiting
- Sponsor
- Hexal AG
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of adalimumab in rheumatoid arthritis (RA), psoriasis and autoimmune disease (2 arms), sponsored by Hexal AG. Primary endpoints: AUC0-360h and Cmax. Started Jan 2015; status: active, not recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)psoriasisautoimmune disease
Beyond the preview
Go deeper on NL-OMON42002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42002.